John P Sheppard1, Vera Ong1, Carlito Lagman1, Methma Udawatta1, Courtney Duong1, Thien Nguyen1, Giyarpuram N Prashant1, David S Plurad2,3, Dennis Y Kim2,3, Isaac Yang1,4,5,6,7,3. 1. Department of Neurosurgery, Ronald Regan UCLA Medical Center, Los Angeles, California. 2. Department of Trauma Surgery, Harbor-UCLA Medical Center, Los Angeles, California. 3. Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Los Angeles, California. 4. Department of Head and Neck Surgery, Ronald Regan UCLA Medical Center, Los Angeles, California. 5. Department of Radiation Oncology, Ronald Regan UCLA Medical Center, Los Angeles, California. 6. Jonsson Comprehensive Cancer Center, Ronald Regan UCLA Medical Center, Los Angeles, California. 7. Department of Neurosurgery, Harbor-UCLA Medical Center, Los Angeles, California.
Abstract
BACKGROUND: External ventricular drain (EVD) placement is essential for the management of many neurocritical care patients. However, ventriculostomy-related infection (VRI) is a serious complication, and there remains no well-established protocol guiding use of perioperative or extended antibiotic prophylaxis to minimize risk of VRI. OBJECTIVE: To analyze published evidence on the efficacy of extended prophylactic antimicrobial therapy and antibiotic-coated external ventricular drains (ac-EVDs) in reducing VRI incidence. METHODS: We searched PubMed for studies related to VRIs and antimicrobial prophylaxis. Eligible articles reported VRI incidence in control and treatment cohorts evaluating prophylaxis with either extended systemic antibiotics (> 24 hr) or ac-EVD. Risk ratios and VRI incidence were aggregated by prophylactic strategy, and pooled estimates were determined via random or mixed effects models. Study heterogeneity was quantified using I2 and Cochran's Q statistics. Rigorous assessment of study bias was performed, and PRISMA guidelines were followed throughout. RESULTS: Across 604 articles, 19 studies (3%) met eligibility criteria, reporting 5242 ventriculostomy outcomes. Extended IV and ac-EVD prophylaxis were associated with risk ratios of 0.36 [0.14, 0.93] and 0.39 [0.21, 0.73], respectively. Mixed effects analysis yielded expected VRI incidence of 13% to 38% with no prophylaxis, 7% to 18% with perioperative IV prophylaxis, 3% to 9% with either extended IV or ac-EVD prophylaxis as monotherapies, and as low as 0.8% to 2% with extended IV and ac-EVD dual prophylaxis. CONCLUSION: Management with both extended systemic antibiotics and ac-EVDs could lower VRI risk in ventriculostomy patients, but the impact on associated morbidity and mortality, healthcare costs, and length of stay remain unclear.
BACKGROUND: External ventricular drain (EVD) placement is essential for the management of many neurocritical care patients. However, ventriculostomy-related infection (VRI) is a serious complication, and there remains no well-established protocol guiding use of perioperative or extended antibiotic prophylaxis to minimize risk of VRI. OBJECTIVE: To analyze published evidence on the efficacy of extended prophylactic antimicrobial therapy and antibiotic-coated external ventricular drains (ac-EVDs) in reducing VRI incidence. METHODS: We searched PubMed for studies related to VRIs and antimicrobial prophylaxis. Eligible articles reported VRI incidence in control and treatment cohorts evaluating prophylaxis with either extended systemic antibiotics (> 24 hr) or ac-EVD. Risk ratios and VRI incidence were aggregated by prophylactic strategy, and pooled estimates were determined via random or mixed effects models. Study heterogeneity was quantified using I2 and Cochran's Q statistics. Rigorous assessment of study bias was performed, and PRISMA guidelines were followed throughout. RESULTS: Across 604 articles, 19 studies (3%) met eligibility criteria, reporting 5242 ventriculostomy outcomes. Extended IV and ac-EVD prophylaxis were associated with risk ratios of 0.36 [0.14, 0.93] and 0.39 [0.21, 0.73], respectively. Mixed effects analysis yielded expected VRI incidence of 13% to 38% with no prophylaxis, 7% to 18% with perioperative IV prophylaxis, 3% to 9% with either extended IV or ac-EVD prophylaxis as monotherapies, and as low as 0.8% to 2% with extended IV and ac-EVD dual prophylaxis. CONCLUSION: Management with both extended systemic antibiotics and ac-EVDs could lower VRI risk in ventriculostomy patients, but the impact on associated morbidity and mortality, healthcare costs, and length of stay remain unclear.
Authors: Setthasorn Zhi Yang Ooi; Robert James Spencer; Megan Hodgson; Samay Mehta; Nicholas Lloyd Phillips; Gwilym Preest; Susruta Manivannan; Matt P Wise; James Galea; Malik Zaben Journal: Neurosurg Rev Date: 2022-07-06 Impact factor: 2.800
Authors: Sei Yon Sohn; Clark D Russell; Aimun A B Jamjoom; Michael T Poon; Aaron Lawson McLean; Aminul I Ahmed Journal: Open Forum Infect Dis Date: 2022-09-17 Impact factor: 4.423
Authors: Charlene Y C Chau; Claudia L Craven; Andres M Rubiano; Hadie Adams; Selma Tülü; Marek Czosnyka; Franco Servadei; Ari Ercole; Peter J Hutchinson; Angelos G Kolias Journal: J Clin Med Date: 2019-09-10 Impact factor: 4.241